Designer Labeling: Drug Safety Reform Proposals Include New Powers for FDA
This article was originally published in RPM Report
Executive Summary
The time has come when the pharmaceutical industry will have to answer for Vioxx. Congress will address drug safety in 2007. That means FDA could get new authority over the heart and soul of any new drug-the label.
You may also be interested in...
The Era of Drug Efficacy
FDA has been perceived by drug developers as a regulator obsessed with drug safety. But recent cases show serious safety concerns aren’t holding back new products: efficacy has been the deciding factor for approval.
FDA Drug Safety Update: Key Takeaways From IoM Workshop
It has been three years since an Institute of Medicine report on FDA's drug safety system, and two years since the landmark FDA Amendments Act that followed. As those anniversaries approached, IoM convened a workshop for an update on the changes at FDA since FDAAA. Here's what we heard.
FDA Drug Safety Update: Key Takeaways From IoM Workshop
It has been three years since an Institute of Medicine report on FDA's drug safety system, and two years since the landmark FDA Amendments Act that followed. As those anniversaries approached, IoM convened a workshop for an update on the changes at FDA since FDAAA. Here's what we heard.